A detailed history of Israel Englander (Millennium Management LLC) transactions in Myriad Genetics Inc stock. As of the latest transaction made, Millennium Management LLC holds 5,176,511 shares of MYGN stock, worth $70.7 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
5,176,511
Previous 4,399,012 17.67%
Holding current value
$70.7 Million
Previous $108 Million 31.68%
% of portfolio
0.07%
Previous 0.05%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.97 - $28.6 $18.6 Million - $22.2 Million
777,499 Added 17.67%
5,176,511 $142 Million
Q2 2024

Aug 14, 2024

BUY
$17.98 - $25.47 $5.84 Million - $8.28 Million
324,974 Added 7.98%
4,399,012 $108 Million
Q1 2024

May 15, 2024

BUY
$17.59 - $23.59 $10.8 Million - $14.5 Million
612,701 Added 17.7%
4,074,038 $86.9 Million
Q4 2023

Feb 14, 2024

BUY
$13.91 - $21.32 $35.5 Million - $54.4 Million
2,552,889 Added 281.02%
3,461,337 $66.2 Million
Q2 2023

Aug 14, 2023

SELL
$17.56 - $23.76 $8.38 Million - $11.3 Million
-476,943 Reduced 34.43%
908,448 $21.1 Million
Q1 2023

May 15, 2023

SELL
$15.26 - $23.75 $1.33 Million - $2.07 Million
-87,025 Reduced 5.91%
1,385,391 $32.2 Million
Q4 2022

Feb 14, 2023

BUY
$14.51 - $20.99 $2.99 Million - $4.33 Million
206,181 Added 16.28%
1,472,416 $21.4 Million
Q3 2022

Nov 14, 2022

BUY
$18.21 - $27.88 $23.1 Million - $35.3 Million
1,266,235 New
1,266,235 $24.2 Million
Q1 2022

May 16, 2022

SELL
$22.67 - $28.01 $20.1 Million - $24.8 Million
-886,758 Reduced 71.99%
344,987 $8.69 Million
Q4 2021

Feb 14, 2022

BUY
$24.13 - $32.63 $13.8 Million - $18.7 Million
572,154 Added 86.74%
1,231,745 $34 Million
Q3 2021

Nov 15, 2021

SELL
$29.97 - $36.66 $7.01 Million - $8.58 Million
-233,929 Reduced 26.18%
659,591 $21.3 Million
Q2 2021

Aug 16, 2021

BUY
$25.39 - $32.61 $214,723 - $275,782
8,457 Added 0.96%
893,520 $27.3 Million
Q1 2021

May 17, 2021

SELL
$19.92 - $31.6 $7.09 Million - $11.2 Million
-355,685 Reduced 28.67%
885,063 $27 Million
Q4 2020

Feb 16, 2021

BUY
$12.16 - $19.77 $1.53 Million - $2.49 Million
126,183 Added 11.32%
1,240,748 $24.5 Million
Q3 2020

Nov 16, 2020

BUY
$11.25 - $14.75 $12.1 Million - $15.8 Million
1,071,697 Added 2499.99%
1,114,565 $14.5 Million
Q2 2020

Aug 14, 2020

SELL
$10.69 - $16.49 $149,061 - $229,936
-13,944 Reduced 24.54%
42,868 $486,000
Q1 2020

May 14, 2020

SELL
$9.78 - $29.53 $6.66 Million - $20.1 Million
-681,426 Reduced 92.3%
56,812 $813,000
Q4 2019

Feb 14, 2020

BUY
$20.93 - $35.1 $15.5 Million - $25.9 Million
738,238 New
738,238 $20.1 Million
Q3 2019

Nov 14, 2019

SELL
$22.08 - $47.08 $37.9 Million - $80.9 Million
-1,718,033 Closed
0 $0
Q2 2019

Aug 15, 2019

SELL
$22.67 - $35.0 $60.4 Million - $93.3 Million
-2,666,447 Reduced 60.82%
1,718,033 $47.7 Million
Q2 2019

Aug 14, 2019

BUY
$22.67 - $35.0 $84 Million - $130 Million
3,703,572 Added 543.92%
4,384,480 $29 Million
Q1 2019

May 14, 2019

BUY
$26.93 - $34.7 $8.87 Million - $11.4 Million
329,220 Added 93.61%
680,908 $22.6 Million
Q4 2018

Feb 14, 2019

SELL
$27.23 - $45.56 $16.8 Million - $28 Million
-615,547 Reduced 63.64%
351,688 $10.2 Million
Q3 2018

Nov 14, 2018

BUY
$37.57 - $50.34 $24 Million - $32.1 Million
637,481 Added 193.32%
967,235 $44.5 Million
Q2 2018

Aug 14, 2018

BUY
$27.75 - $40.17 $8.1 Million - $11.7 Million
291,902 Added 771.17%
329,754 $12.3 Million
Q1 2018

May 15, 2018

SELL
$28.83 - $41.01 $5.67 Million - $8.06 Million
-196,624 Reduced 83.86%
37,852 $1.12 Million
Q4 2017

Feb 14, 2018

SELL
$28.45 - $37.14 $9.32 Million - $12.2 Million
-327,480 Reduced 58.28%
234,476 $8.05 Million
Q3 2017

Nov 14, 2017

BUY
$24.01 - $36.2 $13.5 Million - $20.3 Million
561,956
561,956 $20.3 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.1B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.